Alpha Lipoic Acid Ammonium Bromide Ammonium Carbon
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Alpha Lipoic Acid Ammonium Bromide Ammonium Carbon
- Multi-Ingredient Homeopathic Complex: No Repurposing Prediction Available
Multi-Ingredient Homeopathic Complex: No Repurposing Prediction Available
Note: The INN for this candidate covers 18 components: Alpha Lipoic Acid, Ammonium Bromide, Ammonium Carbonate, Antimony Trisulfide, Artemisia Cina Pre-Flowering Top, Bos Taurus Hypothalamus, Bos Taurus Pituitary Gland Posterior, Delphinium Staphisagria Seed, Fucus Vesiculosus, Garcinia Gummi-Gutta Fruit, Lycopodium Clavatum Spore, Nerium Oleander Whole, Olea Europaea Flower, Oyster Shell Calcium Carbonate Crude, Phosphorus, Semecarpus Anacardium Juice, Sodium Chloride, Thyroid Unspecified.
One-Sentence Summary
This 18-component product contains a mixture of botanical, homeopathic, and glandular ingredients — a profile consistent with naturopathic weight management or thyroid support formulations. However, no original indication is recorded in any regulatory database, and the TxGNN model generated no repurposing predictions for this candidate. As a result, evidence-based evaluation cannot proceed until foundational data are collected.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded (no regulatory approvals found) |
| Predicted New Indication | None — TxGNN produced no prediction for this candidate |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (prerequisite data absent) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
The TxGNN model requires a mapped DrugBank ID and at least one recognized disease association in the knowledge graph to generate a repurposing score.
This candidate has neither: drugbank_id is null, and original_indications is empty.
From the ingredient profile, the product appears to be a homeopathic / naturopathic combination:
- Metabolic/weight management components: Garcinia gummi-gutta (hydroxycitric acid source), Fucus vesiculosus (iodine/thyroid), Alpha lipoic acid (antioxidant, insulin sensitizer)
- Glandular therapy components: Thyroid (unspecified), Bos taurus hypothalamus, Bos taurus pituitary gland posterior
- Classical homeopathic remedies: Lycopodium clavatum, Phosphorus, Delphinium staphisagria, Nerium oleander, Semecarpus anacardium, Artemisia cina
Because none of these 18 components could be matched to a single DrugBank entry as a unit, the pipeline treated the combined INN string as an unknown entity and produced no candidates.
Safety Considerations
Please refer to the package insert for safety information.
No DDI records were found. Key warnings and contraindications data are unavailable and must be sourced from the original product labeling before any clinical evaluation begins.
Conclusion and Next Steps
Decision: Hold
Rationale: The candidate lacks the two minimum inputs needed for TxGNN evaluation — a DrugBank ID and a documented original indication — and has zero regulatory approvals in any jurisdiction. There is no basis for a repurposing assessment at this stage.
To proceed, the following is needed:
- Disaggregate the compound: Evaluate each of the 18 active ingredients individually through TxGNN, or identify the single primary active component for the repurposing query.
- Establish original indication: Retrieve the product’s labeled indication from its country of origin or manufacturer documentation to anchor the evaluation.
- DrugBank mapping: Attempt individual DrugBank ID matching for pharmacologically active components (Alpha Lipoic Acid, Fucus Vesiculosus, Garcinia Gummi-Gutta, Thyroid) that have established DrugBank entries.
- Safety data collection: Download the original product insert (or equivalent label) to resolve the Blocking data gap (DG001) for key warnings and contraindications.
- Regulatory status clarification: Confirm whether this product is registered in any jurisdiction as a dietary supplement, homeopathic product, or pharmaceutical, since the regulatory pathway materially affects what evidence standards apply.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.